Background/aims: Whether the postobstructive natriuresis and diuresis is related with an altered regulation of sodium transporters in the kidney was examined.
Methods: Male Sprague-Dawley rats underwent either bilateral (BUO) or unilateral obstruction (UUO) of the proximal ureters for 24 h. The expression of Na,K-ATPase, type-3 sodium-hydrogen exchanger (NHE3), type-1 bumetanide-sensitive sodium cotransporter (BSC1), and thiazide-sensitive sodium cotransporter (TSC) proteins was determined in the obstructed kidney by Western blot analysis and immunohistochemistry. Catalytic activity of Na,K-ATPase was also determined.
Results: The expression of alpha1 and beta1 subunit proteins and the catalytic activity of Na,K-ATPase were significantly decreased in the obstructed kidney in BUO. The expressions of NHE3, BSC1 and TSC proteins were also significantly decreased. Immunohistochemistry confirmed the downregulation of these sodium transporters in the obstructed kidney. In UUO, the expression of sodium transporters was similarly decreased in the obstructed kidney.
Conclusion: The postobstructive natriuresis and diuresis may in part be accounted for by a reduced abundance of sodium transporters in the kidney.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000076748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The misuse and uncontrolled release of pharmaceuticals into water bodies lead to environmental challenges and the development of resistance, thereby reducing their effectiveness. To mitigate these problems, it is essential to identify pharmaceuticals in water sources and eliminate them prior to human use. This study presents the designing of a novel nanosensor for the detection of the antibiotic Cefoperazone Sodium Sulbactam Sodium (CSSS).
View Article and Find Full Text PDFSodium-glucose co-transporter-2 inhibitor treatment-associated changes in hemoglobin level in anemic patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
Haematologica
January 2025
Division of Hematology, Mayo Clinic, Rochester, Minnesota.
Not available.
View Article and Find Full Text PDFState of precision medicine for heart failure with preserved ejection fraction in a new therapeutic age.
ESC Heart Fail
January 2025
Faculty of Medicine, Royal Brisbane and Women's Hospital, University of Queensland, Herston, Queensland, Australia.
Heart failure with preserved ejection fraction (HFpEF) is defined by heart failure (HF) with a left ventricular ejection fraction (LVEF) of at least 50%. HFpEF has a complex and heterogeneous pathophysiology with multiple co-morbidities contributing to its presentation. Establishing the diagnosis of HFpEF can be challenging.
View Article and Find Full Text PDFAge-dependent effects of SGLT2 inhibitors on stroke risk in geriatric patients with diabetes and atrial fibrillation.
Cardiovasc Diabetol
January 2025
Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan, ROC.
Background: Atrial fibrillation (AF) and diabetes mellitus (DM) are associated with an increased risk of ischemic stroke, particularly in geriatric populations. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated cardiovascular benefits, but their effects on stroke risk may vary by age. This study aimed to explore the age-dependent effects of SGLT2i on stroke risk in patients with AF and DM.
View Article and Find Full Text PDFAssociation of sodium-glucose cotransporter-2 inhibitors with mortality across the spectrum of myocardial infarction: a systematic review and meta-analysis.
Cardiovasc Diabetol
January 2025
Department of Internal Medicine B, University of Medicine Greifswald, Ferdinand-Sauerbruch-Straße, 17475, Greifswald, Germany.
Background: The impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors on mortality following myocardial infarction (MI) remains uncertain. Additionally, the role of type 2 diabetes mellitus (T2DM) and heart failure (HF) in modulating the effectiveness of these drugs post-MI are not fully understood. This meta-analysis aimed to assess the association of SGLT2 inhibitors with all-cause mortality in post-MI patients and to explore key moderators influencing this benefit.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!